| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2003;76:1810-1814
© 2003 The Society of Thoracic Surgeons
a Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
Accepted for publication June 5, 2003.
* Address reprint requests to Dr Ichinose, Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan
e-mail: yichinos{at}nk-cc.go.jp
BACKGROUND: Combination chemotherapy using an oral combination of uracil and tegafur (UFT) plus cisplatin and concurrent thoracic radiotherapy is reported to have a high response rate and less toxicity for locally advanced non–small-cell lung cancer (NSCLC) patients. We performed a phase II trial using this chemoradiotherapy as an induction treatment.
METHODS: Patients with marginally resectable stage IIIB NSCLC, an age younger than 70 years, a performance status of 0 or 1, and good organ function were eligible. The UFT (400 mg/m2) was administered orally on days 1 through 14 and 22 through 35 and cisplatin (80 mg/m2) was injected intravenously on days 8 and 29. Radiotherapy with a total dose of 40 Gy was delivered in 20 fractions from day 1. A surgical resection was performed from 3 to 6 weeks after completing the induction treatment.
RESULTS: Twenty-seven patients, 18 male and 9 female with a median age of 56 years and ranging from 36 to 69 years, were entered into the phase II trial. Clinical T4 and N3 cancers were observed in 22 and 7 patients, respectively. Twenty-five (93%) achieved a partial response. The most frequently observed adverse event was grade 3 leukopenia in 26%. Of 25 patients who underwent a thoracotomy, 22 had a tumor resection. In all 22 patients a complex resection including a resection of the superior vena cava, carina, and vertebrae was required. Operative morbidity and mortality rates were 36% and 4% respectively. The calculated 1-year and 3-year survival rates of all 27 patients were 73% and 56% respectively.
CONCLUSIONS: Chemotherapy using UFT plus cisplatin and concurrent radiotherapy as induction treatment and a surgical resection for patients with marginally resectable stage IIIB NSCLC is feasible and promising. However it is difficult to conduct multi-institutional trials even for selected stage IIIB disease as a complex resection in almost all patients is necessary.
This article has been cited by other articles:
|
|
 |
|
  M. Anraku, T. K. Waddell, M. de Perrot, S. J. Lewis, A. F. Pierre, G. E. Darling, M. R. Johnston, R. E. Zener, Y. R. Rampersaud, F. A. Shepherd, et al. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. J. Thorac. Cardiovasc. Surg., February 1, 2009; 137(2): 441 - 447.e1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. T. Wang, W. Sienel, S. Eggeling, C. Ludwig, E. Stoelben, J. Mueller, C. A. Klein, and B. Passlick Detection of disseminated tumor cells in mediastinoscopic lymph node biopsies and lymphadenectomy specimens of patients with NSCLC by quantitative RT-PCR Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
